Pathogenic rare copy number variants in community-based schizophrenia suggest a potential role for clinical microarrays
Authors:
Open Access
- 27 June 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 22 (22) , 4485-4501
Abstract
Individually rare, large copy number variants (CNVs) contribute to genetic vulnerability for schizophrenia. Unresolved questions remain, however, regarding the anticipated yield of clinical microarray testing in schizophrenia. Using high-resolution genome-wide microarrays and rigorous methods, we investigated rare CNVs in a prospectively recruited community-based cohort of 459 unrelated adults with schizophrenia and estimated the minimum prevalence of clinically significant CNVs that would be detectable on a clinical microarray. A blinded review by two independent clinical cytogenetic laboratory directors of all large (>500 kb) rare CNVs in cases and well-matched controls showed that those deemed to be clinically significant were highly enriched in schizophrenia (16.4-fold increase, P < 0.0001). In a single community catchment area, the prevalence of individuals with these CNVs was 8.1%. Rare 1.7 Mb CNVs at 2q13 were found to be significantly associated with schizophrenia for the first time, compared with the prevalence in 23 838 population-based controls (42.9-fold increase, P = 0.0002). Additional novel findings that will facilitate the future clinical interpretation of smaller CNVs in schizophrenia include: (i) a greater proportion of individuals with two or more rare exonic CNVs >10 kb in size (1.5-fold increase, P = 0.0109) in schizophrenia; (ii) the systematic discovery of new candidate genes for schizophrenia; and, (iii) functional gene enrichment mapping highlighting a differential impact in schizophrenia of rare exonic deletions involving diverse functions, including neurodevelopmental and synaptic processes (4.7-fold increase, P = 0.0060). These findings suggest consideration of a potential role for clinical microarray testing in schizophrenia, as is now the suggested standard of care for related developmental disorders like autism.Keywords
This publication has 69 references indexed in Scilit:
- Exome Sequencing Followed by Large-Scale Genotyping Suggests a Limited Role for Moderately Rare Risk Factors of Strong Effect in SchizophreniaThe American Journal of Human Genetics, 2012
- Copy Number Variants for Schizophrenia and Related Psychotic Disorders in Oceanic Palau: Risk and Transmission in Extended PedigreesBiological Psychiatry, 2011
- Recurrent deletions and reciprocal duplications of 10q11.21q11.23 including CHAT and SLC18A3 are likely mediated by complex low-copy repeatsHuman Mutation, 2011
- Clinically detectable copy number variations in a Canadian catchment population of schizophreniaJournal of Psychiatric Research, 2010
- Inference of Unexpected Genetic Relatedness among Individuals in HapMap Phase IIIThe American Journal of Human Genetics, 2010
- Consensus Statement: Chromosomal Microarray Is a First-Tier Clinical Diagnostic Test for Individuals with Developmental Disabilities or Congenital AnomaliesThe American Journal of Human Genetics, 2010
- Extracardiac features predicting 22q11.2 Deletion Syndrome in adult congenital heart diseaseInternational Journal of Cardiology, 2008
- Recurrent CNVs Disrupt Three Candidate Genes in Schizophrenia PatientsThe American Journal of Human Genetics, 2008
- Structural Variation of Chromosomes in Autism Spectrum DisorderThe American Journal of Human Genetics, 2008
- Schizophrenia in an adult with 6p25 deletion syndromeAmerican Journal of Medical Genetics Part A, 2006